PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later

Ann Oncol. 2021 Dec;32(12):1460-1462. doi: 10.1016/j.annonc.2021.10.005. Epub 2021 Oct 19.

Authors

J Fuentes-Antrás¹, D W Cescon²

Affiliations

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada.
² Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada. Electronic address: [email protected].

PMID: 34678412
DOI: 10.1016/j.annonc.2021.10.005

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Kommentar

MeSH terms

Antineoplastic Agents* / therapeutic use
Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Female
Humans
Phthalazines / therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use

Substances

Antineoplastic Agents
Phthalazines
Poly(ADP-ribose) Polymerase Inhibitors